BR112013024323A2 - peptídeos neuroprotetores - Google Patents

peptídeos neuroprotetores

Info

Publication number
BR112013024323A2
BR112013024323A2 BR112013024323A BR112013024323A BR112013024323A2 BR 112013024323 A2 BR112013024323 A2 BR 112013024323A2 BR 112013024323 A BR112013024323 A BR 112013024323A BR 112013024323 A BR112013024323 A BR 112013024323A BR 112013024323 A2 BR112013024323 A2 BR 112013024323A2
Authority
BR
Brazil
Prior art keywords
neuroprotective peptides
neuroprotective
peptides
Prior art date
Application number
BR112013024323A
Other languages
English (en)
Inventor
Zisapel Nava
Elhanan Pinner
Original Assignee
Neurim Pharmaceuticals ( 1991 ) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals ( 1991 ) Ltd filed Critical Neurim Pharmaceuticals ( 1991 ) Ltd
Publication of BR112013024323A2 publication Critical patent/BR112013024323A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585CD44
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112013024323A 2011-03-24 2012-03-22 peptídeos neuroprotetores BR112013024323A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161466966P 2011-03-24 2011-03-24
PCT/IL2012/050104 WO2012127475A1 (en) 2011-03-24 2012-03-22 Neuroprotective peptides

Publications (1)

Publication Number Publication Date
BR112013024323A2 true BR112013024323A2 (pt) 2017-06-13

Family

ID=45999925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013024323A BR112013024323A2 (pt) 2011-03-24 2012-03-22 peptídeos neuroprotetores

Country Status (13)

Country Link
US (1) US20140045764A1 (pt)
EP (1) EP2688582B1 (pt)
JP (1) JP5960793B2 (pt)
KR (1) KR20140036164A (pt)
CN (1) CN103648517B (pt)
AU (1) AU2012232642B2 (pt)
BR (1) BR112013024323A2 (pt)
CA (1) CA2830792A1 (pt)
EA (1) EA201391387A1 (pt)
MX (1) MX2013010910A (pt)
SG (1) SG193418A1 (pt)
WO (1) WO2012127475A1 (pt)
ZA (1) ZA201307169B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
EP3409130B1 (en) * 2016-01-27 2020-11-25 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors
US10981956B2 (en) 2016-03-31 2021-04-20 Senju Pharmaceutical Co., Ltd. Neuroprotective peptide
US10660934B2 (en) 2016-03-31 2020-05-26 Senju Pharmaceutical Co., Ltd. Neuroprotective peptide
CN111344300B (zh) 2017-11-14 2024-08-30 千寿制药株式会社 Pacap的稳定化肽
AU2019374743B2 (en) 2018-11-08 2022-03-03 Neovasc Tiara Inc. Ventricular deployment of a transcatheter mitral valve prosthesis
EP3974027B1 (en) 2019-05-14 2024-10-23 Senju Pharmaceutical Co., Ltd. Stabilized pacap peptide
EP3970796A4 (en) 2019-05-14 2022-12-21 Senju Pharmaceutical Co., Ltd. COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS CONTAINING A PACAP-LIKE PEPTIDE OR A STABILIZED PACAP-LIKE PEPTIDE
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1995000658A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
CA2179391A1 (en) * 1994-01-18 1995-07-20 Edgar Haber Cd44 expression in smooth muscle cells
DE19653607A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
WO1999037317A1 (en) * 1998-01-24 1999-07-29 Bristol-Myers Squibb Company Artificial proteoglycans
DK1647556T3 (da) * 2004-10-14 2010-07-19 Karlsruher Inst Technologie Peptidforbindelser og derivater deraf til behandling af sygdomme hos mennesker ved inhibering af signaloverførsel via vækstfaktorer
CN101821407B (zh) * 2007-07-10 2013-09-18 纽瑞姆制药(1991)有限公司 神经退行性疾病中的cd44剪接变体
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases

Also Published As

Publication number Publication date
CA2830792A1 (en) 2012-09-27
MX2013010910A (es) 2014-03-27
EA201391387A1 (ru) 2014-01-30
AU2012232642A1 (en) 2013-10-17
JP2014510101A (ja) 2014-04-24
CN103648517A (zh) 2014-03-19
KR20140036164A (ko) 2014-03-25
EP2688582A1 (en) 2014-01-29
JP5960793B2 (ja) 2016-08-02
CN103648517B (zh) 2016-04-20
ZA201307169B (en) 2014-05-28
EP2688582B1 (en) 2017-02-15
SG193418A1 (en) 2013-10-30
AU2012232642B2 (en) 2016-12-08
WO2012127475A1 (en) 2012-09-27
US20140045764A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
NL301241I2 (nl) Belantamab mafodotin
BR112014004902A2 (pt) peptídeos
CO7020866A2 (es) Péptidos terapéuticos
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
DK2797616T3 (da) Celle-penetrerende peptider
DK2769050T3 (da) Propsensor
BR112014000879A2 (pt) deflegmador
DE102011100082A8 (de) Traygreifvorrichtung
BR112013024323A2 (pt) peptídeos neuroprotetores
DK3141251T3 (da) Koloskopi - forberedelse
CL2014002180A1 (es) Peptidos antomicrobianos
DE112011104936A5 (de) Stanzstauchniet
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
BR112013009679A2 (pt) peptídeo
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
FR2976926B1 (fr) Caisse-outre
FI20115354A0 (fi) Kampikammion luukku
DE102011117169A8 (de) Absetzplattenanordnung
DE112011105396A5 (de) Nachverfestigungsverfahren
IL228354A0 (en) Neuroprotective peptides

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]